QualityStocks would like to highlight International Stem Cell Corp. (OTCBB: ISCO). International Stem Cell is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups.
In the company’s news Friday,
International Stem Cell Corp., the first company to successfully create a human “parthenogenetic” stem cell from unfertilized human eggs, announced it is working in collaboration with tissue engineers at Cytograft Tissue Engineering to make headway in human vascular grafts.
Scientists at International Stem Cells’ subsidiary, Lifeline Cell Technology, will work with Cytrograft to develop and produce a customized cell culture to cultivate living human grafts, which is anticipated to be an advancement over previously used materials.
Todd McAllister Ph.D., CEO of Cytograft, stated, “The team at Lifeline Cell Technologies is uniquely qualified to develop and design custom media formulations for our application. They clearly have one of the best scientific teams in the field, and, importantly, have a service based business model that has been flexible and responsive to our specific requirements.”
Jeffrey Janus, CEO of Lifeline Cell Technology seems equally impressed with Cytrografts technologies and position in the advances of vascular grafts.
Cytograft’s current technology is called Lifeline. According to the press release, the technology has several applications, including: as a coronary graft for coronary bypass procedures; as a peripheral graft to prevent lower limb amputations; and as a living tissue shunt for hemodialysis patients.
“It is an honor that Cytograft chose Lifeline Cell Technology’s team to develop their medium. Their process of growing human vascular grafts promises to be a vast improvement over synthetic materials. Since the grafts are grown using the patient’s own cells, they will minimize the chance of immune rejection, infection and disease transmission,” Janus stated.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
